We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
South African generics producer Aspen Pharmacare has outlined
plans to carry out a major expansion, and could launch up to 100 new products
as leading drugs come off patent in the coming years.
According to local reports, senior Indian government figures have effectively
overruled plans outlined by the country's chemicals ministry to restrict margins
on pharmaceutical products not subject to official price controls.
The chairman of leading Indian generics producer Dr. Reddy's has urged the local
sector to increase the volume of its contract research activity, as opposed
to out-licensing discovery work to overseas companies.
Australia-based veterinary drug producer Chemeq has
announced that it has received an AUD60mn (US$45.51mn) investment stream from
a UK-based financial securities unit of Japanese bank Mizuho.
Israeli sources have reported that financial studies, conducted by US banking
giant Bank of America (BofA) on generics major Teva, indicate that the company
could become an acquisition target for drug majors in 2005.
Switzerland-based drug major Novartis has pledged to invest
some BRL100mn (US$36.78mn) on its Brazilian operations in 2005, but has criticised
the government's willingness to break patents on HIV/AIDS treatments.